Last reviewed · How we verify
ex vivo Activated Immune Cells — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ex vivo Activated Immune Cells (ex vivo Activated Immune Cells) — B & Y Technologies.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ex vivo Activated Immune Cells TARGET | ex vivo Activated Immune Cells | B & Y Technologies | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ex vivo Activated Immune Cells CI watch — RSS
- ex vivo Activated Immune Cells CI watch — Atom
- ex vivo Activated Immune Cells CI watch — JSON
- ex vivo Activated Immune Cells alone — RSS
Cite this brief
Drug Landscape (2026). ex vivo Activated Immune Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/ex-vivo-activated-immune-cells. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab